China Resources Pharmaceutical Group Ltd. has filed for an initial public offering in Hong Kong that could rank it among the biggest health-care-related deals expected this year in Asia, reports The Wall Street Journal. The company, the pharmaceutical arm of one of China’s biggest conglomerates, is looking to raise more than $1 billion and could potentially list shares as soon as September, according to a person familiar with the matter. China Resources Pharma will join a clutch of Chinese pharmaceutical companies lining up to raise collectively more than $5 billion in Hong Kong IPOs this year, according to bankers working on the deals.
China Resources Pharmaceutical in Hong Kong IPO
Related Articles
-
A new lunar year
-
China launches investigation into corporate bonds following wave of defaults
-
Chinese investors ignore government and flock to safer bonds
-
Chinese stocks see strong start to 2019
-
Two major Chinese borrowers miss bond payments, Bloomberg says
-
Chinese innovation: threat or opportunity?
-
HIV reports force investigation of Chinese pharma company
-
Why China’s trade policies are not as “unorthodox” as the US thinks
You must log in to post a comment.